Compare Cytokinetics Inc (CYTK) vs HP Inc (HPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs HP Inc — how do they compare? Cytokinetics Inc trades at $62.64 (market cap $8.62B), while HP Inc trades at $30.54 (market cap $29.25B). The key difference: HP Inc is far larger — about 3.4× Cytokinetics Inc's market cap, and HP Inc pays a 3.7% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and HP Inc for 70 Days on average.
| CYTK | HPQ | |
|---|---|---|
Market Cap | $8.62B | $29.25B |
Volume | 2,594,626 | 10,025,806 |
Sector | Health | Technology |
52-Week High | $87.26 | $35.48 |
52-Week Low | $54.76 | $18.20 |
Typical Hold Time | 19 Days | 70 Days |
Enterprise Value | $8.72B | $35.42B |
Dividend Yield | — | 3.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
HPQ trades at $32.24, up 1.61% with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, maintaining stable revenue around $55B with a 4.14% net margin. Recent news highlights HP's new PC launches and AI capabilities, though the stock faces headwinds from a projected mid-single-digit PC market decline in 2027.
The outlook is mixed: valuation appears reasonable with a P/E of 12.38 and P/S of 0.51, and strong cash flow supports dividends. However, negative shareholder equity and competitive pressures in the PC market present risks. Analyst consensus is cautious with a $25.75 price target below current levels, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →
